<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485209</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTV-001</org_study_id>
    <secondary_id>2017-005076-26</secondary_id>
    <nct_id>NCT03485209</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors</brief_title>
  <acronym>innovaTV 207</acronym>
  <official_title>Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study tisotumab vedotin to find out whether it is an effective treatment for
      certain solid tumors and what side effects (unwanted effects) may occur. There are two parts
      to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week
      cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every
      4-week cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this trial is to assess the activity, safety, and tolerability of
      tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with
      single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into
      cohorts based on tumor type. Tumor types to be evaluated include colorectal cancer, squamous
      non-small cell lung cancer (NSCLC), exocrine pancreatic adenocarcinoma, and squamous cell
      carcinoma of the head and neck (SCCHN).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1 as assessed by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Type, severity, and relatedness of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed and Unconfirmed ORR</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator, or meet the SD criteria at least once after start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Time from the first documentation of objective response to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Time from the start of study treatment to the first documentation of objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Time from the start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Through 8 days after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Through 8 days after dosing</time_frame>
    <description>Observed plasma concentration at the end of the dosing interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Exocrine Pancreatic Cancer</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin - Q3W Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisotumab Vedotin [2.0 mg/kg] every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin - 3Q4W Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisotumab Vedotin [0.9 mg/kg or 1.2 mg/kg] on Days 1, 8, and 15 of 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tisotumab vedotin</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Tisotumab Vedotin - 3Q4W Regimen</arm_group_label>
    <arm_group_label>Tisotumab Vedotin - Q3W Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer, squamous
             NSCLC, or SCCHN patients who are not candidates for standard therapy.

          -  All patients must have experienced disease progression on or after their most recent
             systemic therapy.

          -  Baseline measurable disease as measured by RECIST v1. 1.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

          -  Colorectal cancer patients must have received prior therapy with each of following
             agents, if eligible: a fluoropyrimidine, oxaliplatin, irinotecan, and/or bevacizumab.
             Patients should have received no more than 3 systemic regimens in the metastatic
             setting.

          -  Patients with NSCLC must have predominant squamous histology. Patients must have
             received prior therapy with a platinum-based treatment and a checkpoint inhibitor
             (CPI), if eligible. Patients should have received no more than 2 systemic regimens in
             the metastatic setting.

               -  Patients eligible for a tyrosine kinase inhibitor should have received such
                  therapy. These patients should have received no more than 3 systemic regimens in
                  the metastatic setting.

          -  Patients with exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma
             histology. Patients must have received prior therapy with a gemcitabine-based or
             5FU-based regimen, if eligible, and should have received no more than 1 systemic
             regimen in the unresectable or metastatic setting.

          -  Patients with SCCHN must have received prior therapy with a platinum-based regimen and
             a checkpoint inhibitor (CPI), if eligible, and should have received no more than 3
             systemic regimens in the recurrent/metastatic setting.

        Exclusion Criteria:

          -  Active bleeding conditions

          -  Ocular surface disease at the time of enrollment (Note: cataract is not considered
             active ocular surface disease for this protocol)

          -  Pulmonary disease requiring chronic medical therapy, unrelated to underlying cancer

          -  Uncontrolled tumor-related pain

          -  Peripheral neuropathy greater than or equal to Grade 2

          -  History of another malignancy within 3 years of the first dose of study drug, or any
             evidence of residual disease from a previously diagnosed malignancy.

          -  Active or previous brain metastasis

          -  Patients who are breastfeeding, pregnant, or planning to become pregnant from the time
             of informed consent until 6 months after the final study dose is administered

          -  For patients with SCCHN or NSCLC, ongoing anticoagulant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shweta Jain, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>8663337436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Ardunio</last_name>
      <phone>916-734-8512</phone>
      <email>earduino@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Devisser</last_name>
      <phone>916-734-1787</phone>
      <email>cdevisser@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>May Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center / Blood and Marrow Transplant Program</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hann</last_name>
      <phone>408-426-4900</phone>
      <email>bhann@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Omid Tehrani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Health System (PVHS)</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Saller</last_name>
      <phone>970-297-6154</phone>
      <email>Jennifer.Saller@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wiess</last_name>
      <phone>203-737-3472</phone>
      <email>christina.wiess@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Lacy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Cancer Center / University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashton Monismith</last_name>
      <phone>352-265-0680</phone>
      <email>amonismith@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care / Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Marriott</last_name>
      <phone>708-339-4800</phone>
      <email>mmarriott@ingalls.org</email>
    </contact>
    <investigator>
      <last_name>Danielle Sterrenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Truesdale</last_name>
      <phone>913-588-6029</phone>
      <email>mhintz@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Anwaar Saeed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Conway</last_name>
      <phone>502-629-4267</phone>
      <email>catherine.conway@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>John Hamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wolanski</last_name>
      <phone>617-632-6623</phone>
      <email>awolanski@partners.org</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Gavenda</last_name>
      <phone>952-993-6071</phone>
      <email>Alissa.Gavenda@ParkNicollet.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Futamura</last_name>
      <phone>646-962-2064</phone>
      <email>emf4001@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Navjot Kaur</last_name>
      <phone>646-962-2064</phone>
      <email>nak2028@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeta Popa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garbarino</last_name>
      <phone>984-974-8662</phone>
      <email>jennifer_garbarino@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center / Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Averill</last_name>
      <phone>336-716-2011</phone>
      <email>saverill@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Thomas</last_name>
      <phone>336-716-2011</phone>
      <email>jethomas@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lowell Hart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Moher</last_name>
      <phone>503-494-3606</phone>
      <email>moher@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Vuky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Vatkevich</last_name>
      <phone>401-444-6217</phone>
      <email>John.vatkevich@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Howard Safran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Burks</last_name>
      <phone>214-818-2591</phone>
      <email>Natasha.Burks@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Carlos Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meiyue Hong</last_name>
      <phone>713-745-4367</phone>
      <email>mghong@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane Flores</last_name>
      <phone>806-725-7993</phone>
      <email>maryjane.Flores@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Isaac Tafur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Mouton</last_name>
      <phone>713-703-2398</phone>
      <email>Alice.mouton@renovatioclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mary Crow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sallie Mannen</last_name>
      <phone>434-297-5724</phone>
      <email>SBM8QZ@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Reilley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta / Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Khaleel</last_name>
      <phone>780-577-8137</phone>
      <email>Maha.Khaleel@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer Spratlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitalier Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christophe Borg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre léon Bérard</name>
      <address>
        <city>LYON cedex 08</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Fayette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sebastien Salas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhr-Uni. Bochum, St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Anke Reinacher-Schick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Università degli Studi di Napoli, AOU</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Fortunato Ciardiello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Ospedale Civile S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Federico Cappuzzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PU Campus Bio-medico di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tonini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>José Luis Manzano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Barcelona Instituto Oncologico Baselga</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip Font</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Alonso Gordoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys And St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>James Spicer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>CRC</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

